NIDA Home > Publications > Research Monographs > | |
Testing for Abuse Liability of Drugs in Humans |
|
NIDA Research Monograph, Number 92 [Printed in 1989]If you have the Acrobat reader plug-in for Netscape or Internet Explorer click on the document link and you will be able to view and/or print out the pages. If you have trouble viewing the document in your browser window, download the document (Windows users - right click on the link and Save as...) to your computer and get Adobe Acrobat Reader (free) in order to view it. This monograph is not available by chapter. The Table of Contents (below) is shown to assist in locating information prior to downloading the monograph. Download Monograph92.pdf - Testing for Abuse Liability of Drugs in Humans (2.2 MB) Table of Contents Introduction Testing and Abuse Liability of Drugs in Humans-----1 The Necessity and Utility of Abuse Liability Evaluations in Human Subjects: The FDA Perspective-----7 The Role of Abuse Liability Testing in Drug Control Procedures-----21 Historical Perspectives on the Use of Subjective Effects Measures in Assessing the Abuse Potential of Drugs-----43 Drug Identification and Classification Human Abuse Liability Assessment by Measurement of Subjective and Physiological Effects-----73 Drug Discrimination: Methods for Drug Characterization and Classification-----101 Assessment of the Reinforcing Properties Abuse Liability of Anxiolytics and Sedative/Hypnotics: Methods Assessing the Likelihood of Abuse-----123 Drug Self-Administration Procedures: Alcohol and Marijuana-----147 The Use of Choice Procedures for Assessing the Reinforcing Properties of Drugs in Humans-----171 Relationship Between Self-Reported Drug Effects and Their Reinforcing Effects: Studies with Stimulant Drugs-----211 Epidemiologic Assessment of Drug Abuse of Drugs Case Reports and the Assessment of Drug Abuse Liability-----231 United States Epidemiologic Data on Drug Use and Abuse: How are They Relevant to Testing Abuse Liability of Drugs?-----241 Current Approaches to Measurements of Drug Use and Abuse in Sweden-----267 Evaluation of the Abuse Liability of Drugs in Humans: Issues and Future Directions Pharmacokinetic and Phartnacodynamic Drug Interactions: Implications for Abuse Liability Testing-----287 Promising New Biologic and Behavioral Correlates of the Reinforcing Properties of Drugs-----307 Drug Abuse Liability Testing: Human Subject Issues-----341 Issues in Human Drug Abuse Liability Testing: Overview and Prospects for the Future-----357 Conference Summary and Perspectives on Human Drug Abuse Liability Testing-----371 Index-----377 List of NIDA Research Monographs-----393 |
|
Advanced Search | FAQs | Accessibility | Site Map | Help | NIDA Home | Privacy Policy | FOIA (NIH) | Employment | Print Version | ||
The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Wednesday, September 18, 2002. |